In a patient weighing ___ kg with an Enterobacter cloacae wound infection that is resistant to multiple agents but susceptible to cefepime, what cefepime dose and treatment duration should be administered?

Cefepime Dosing for Multidrug-Resistant Enterobacter cloacae Wound Infection

For a wound infection caused by multidrug-resistant Enterobacter cloacae that is susceptible to cefepime, administer cefepime 2 g IV every 8-12 hours for 7-10 days, with the specific interval and duration determined by infection severity and clinical response.

Dosing Rationale

The FDA-approved dosing for moderate to severe skin and soft tissue infections is 2 g IV every 12 hours for 10 days 1. However, for infections caused by organisms with potential AmpC β-lactamase production like Enterobacter cloacae—even when reported as cefepime-susceptible—more aggressive dosing may be warranted.

Key Dosing Considerations:

• Standard wound infection: 2 g IV every 12 hours 1
• Severe infection or concern for high bacterial burden: 2 g IV every 8 hours 2, 1
• Infusion time: Administer over approximately 30 minutes 1

The more frequent dosing interval (every 8 hours) is particularly important for Enterobacter species because:

1. AmpC hyperproduction risk: Even susceptible Enterobacter cloacae can develop resistance during therapy through AmpC derepression 3, 4
2. Inoculum effect: Deep-seated or high-burden infections may require higher drug exposure 5
3. Pharmacodynamic optimization: More frequent dosing maintains free drug concentrations above the MIC for a greater percentage of the dosing interval 6

Duration of Therapy

7-10 days is the recommended duration for complicated skin and soft tissue infections 2, 1. The specific duration should be based on:

• 7 days: Adequate for most wound infections with good source control and rapid clinical improvement
• 10 days: Preferred for severe infections, delayed source control, or slow clinical response
• Extend beyond 10 days: Only if inadequate source control or persistent signs of infection

The 2022 MDRO guidelines support 5-7 days for complicated intra-abdominal infections with adequate source control 7, suggesting that with proper wound management, shorter durations may be sufficient.

Critical Management Points

Weight-Based Considerations

While you mentioned patient weight, standard adult dosing (2 g) does not require weight-based adjustment unless the patient is morbidly obese (BMI >40 kg/m²), in which case the same 2 g every 8 hours regimen is appropriate 8.

Renal Function Adjustment

This dosing assumes normal renal function (CrCl >60 mL/min). If creatinine clearance is ≤60 mL/min, dose reduction is mandatory 1:

• CrCl 30-60 mL/min: 2 g every 24 hours
• CrCl 11-29 mL/min: 2 g every 24 hours (loading) then 1 g every 24 hours
• CrCl ≤10 mL/min: 1 g every 24 hours

Source Control

Adequate wound debridement and drainage are essential. Antibiotic therapy alone is insufficient for wound infections without proper surgical management 2. The duration of therapy should be extended if source control is delayed or incomplete.

Monitoring and Pitfalls

Common Pitfalls to Avoid:

1. Underdosing: Using 1 g every 12 hours for Enterobacter infections risks treatment failure due to AmpC induction 5, 3
2. Ignoring renal function: Failure to adjust for renal impairment increases neurotoxicity risk 1
3. Premature discontinuation: Stopping at 5 days may be inadequate for wound infections without excellent source control
4. Assuming susceptibility equals efficacy: Recent data show that 2-3% of Enterobacter cloacae complex isolates are cefepime-resistant despite being AmpC producers without ESBLs or carbapenemases 3

When to Consider Alternative Therapy:

• Clinical failure at 48-72 hours: Consider carbapenem therapy, as recent evidence suggests carbapenems may have superior outcomes for deep-seated AmpC-producing Enterobacterales infections 5
• Cefepime MIC ≥4 μg/mL: Even if reported as "susceptible," consider carbapenem or newer β-lactam/β-lactamase inhibitor combinations
• Bacteremia or severe sepsis: Carbapenem therapy may be preferred over cefepime for serious AmpC-E infections 5, 9

Clinical Monitoring:

Monitor for clinical improvement (reduced erythema, drainage, pain) by day 3-5. If no improvement or worsening occurs, reassess susceptibility testing, ensure adequate source control, and consider switching to a carbapenem (meropenem 1 g IV every 8 hours or imipenem 500 mg IV every 6 hours) 2, 5.